EUVIMEDEUVIMED entdecken
Crossref

Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary

Hiroaki Tanioka, Takeshi Nagasaka

Digestive Medicine Research · 2020

DOI: 10.21037/dmr-20-100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Medicine Research, 2020. Verfasst von Hiroaki Tanioka und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Tanioka, H., & Nagasaka, T. (2020). Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary. Digestive Medicine Research. https://doi.org/10.21037/dmr-20-100

Vancouver

Tanioka H, Nagasaka T. Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary. Digestive Medicine Research. 2020. doi:10.21037/dmr-20-100

BibTeX
@article{Tanioka2020,
  author = {Tanioka, Hiroaki and Nagasaka, Takeshi},
  title = {Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary},
  journal = {Digestive Medicine Research},
  year = {2020},
  doi = {10.21037/dmr-20-100}
}
Kostenlos starten →